Filter by

  • Publication Year
  • Availability
  • Attachment
  • Collection Type
    See More
  • General Material Designation
    See More
  • Location
    See More
  • Language
Found 6 from your keywords: subject="Trolip"
cover
Metabolic syndrome update
Comment Share
Grundy SM

The metabolicsyndromeisamultiplexriskfactorforatheroscleroticcardiovasculardiseaseandtype2diabetes.Itiscomposed of atherogenicdyslipidemia,elevatedbloodpressure,insulinresistanceandelevatedglucose,apro-thromboticstate,anda pro-inflammatorystate.Excessenergyintakeandconcomitantobesityarethemajordriversofthesyndrome.Lifestyle intervention canreversemetabolicriskfactors,butattimes,drugtherapies…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Metabolic syndrome : Pathophysiology, Management, and Modulation by Natural C…
Comment Share
Yogita Rochlan

Metabolic syndrome (MetS) represents a cluster of metabolic abnormalities that include hypertension, central obesity, insulin resistance, and atherogenic dyslipidemia, and is strongly associated with an increased risk for developing diabetes and atherosclerotic and nonatherosclerotic cardiovascular disease (CVD). The pathogenesis of MetS involves both genetic and acquired factors that contribut…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF END…
Comment Share
Jellinger PS

The development of these guidelines is mandated by the American Association of Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology (ACE) Board of Trustees and adheres with published AACE protocols for the standardized production of clinical practice guidelines (CPGs)

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Fenofibrate : A Review of its Use in Primary Dyslipidaemia, the Metabolic Syn…
Comment Share
Keating GM

Fenofibrate is a fibric acid derivative indicated for use in the treatment of primary hypercholesterolaemia, mixed dyslipidaemia and hypertriglyceridaemia in adults who have not responded to nonpharmacological measures. Its lipid-modifying effects are mediated by activation of peroxisome proliferator-activated receptor-α. Fenofibrate also has nonlipid (i.e. pleiotropic) effects (e.g. it reduce…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseli…
Comment Share
The FIELD Study

The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study is examining the effects of long-term fibrate therapy on coronary heart disease (CHD) event rates in patients with diabetes mellitus. This article describes the trial's run-in phase and patients' baseline characteristics

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Fenofibrate: A Review of its Use in Dyslipidaemia
Comment Share
McKeage K

Fenofibrate is a fibric acid derivative indicated for the treatment of severe hypertriglyceridaemia and mixed dyslipidaemia in patients who have not responded to nonpharmacological therapies. The lipid-modifying effects of fenofibrate are mediated by the activation of peroxisome proliferator-activated receptor-a. Fenofibrate also has nonlipid, pleiotropic effects (e.g. reducing levels of fibrin…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-